Chapter 3: Steroid-sensitive nephrotic syndrome in children

Kidney International Supplements

Volumn 2, Issue 2, 2012, Pages 163-171

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042106348     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2012.16     Document Type: Article

References (78)

1. McKinney, P.A., Feltbower, R.G., Brocklebank, J.T., et al. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol 16 (2001), 1040–1044.
2. A Report of the International Study of Kidney Disease in Children, Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int 20 (1981), 765–771.
3. Fakhouri, F., Bocquet, N., Taupin, P., et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41 (2003), 550–557.
4. Koskimies, O., Vilska, J., Rapola, J., et al. Long-term outcome of primary nephrotic syndrome. Arch Dis Child 57 (1982), 544–548.
5. Tarshish, P., Tobin, J.N., Bernstein, J., et al. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8 (1997), 769–776.
6. Arneil, G.C., 164 children with nephrosis. Lancet 2 (1961), 1103–1110.
7. Ruth, E.M., Kemper, M.J., Leumann, E.P., et al. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147 (2005), 202–207.
8. Bhimma, R., Coovadia, H.M., Adhikari, M., Nephrotic syndrome in South African children: changing perspectives over 20 years. Pediatr Nephrol 11 (1997), 429–434.
9. Kim, J.S., Bellew, C.A., Silverstein, D.M., et al. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 68 (2005), 1275–1281.
10. Arneil, G.C., The nephrotic syndrome. Pediatr Clin North Am 18 (1971), 547–559.
11. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of ‘Arbetsgemeinschaft fur Padiatrische Nephrologie’. Lancet 1 (1979), 401–403.
12. Hodson, E.M., Knight, J.F., Willis, N.S., et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev, CD001533, 2005.
13. Feber, J., Al-Matrafi, J., Farhadi, E., et al. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent?. Pediatr Nephrol 24 (2009), 1027–1031.
14. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98 (1981), 561–564.
15. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Lancet 1 (1988), 380–383.
16. Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report of ‘Arbeitsgemeinschaft fur Padiatrische Nephrologie’. Eur J Pediatr 135 (1981), 229–237.
17. Broyer, M., Guest, G., Gagnadoux, M.F., Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr 120 (1992), 721–725.
18. Letavernier, B., Letavernier, E., Leroy, S., et al. Prediction of high-degree steroid dependency in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol 23 (2008), 2221–2226.
19. Noer, M.S., Predictors of relapse in steroid-sensitive nephrotic syndrome. Southeast Asian J Trop Med Public Health 36 (2005), 1313–1320.
20. Lewis, M.A., Baildom, E.M., Davis, N., et al. Nephrotic syndrome: from toddlers to twenties. Lancet 1 (1989), 255–259.
21. Andersen, R.F., Thrane, N., Noergaard, K., et al. Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. Pediatr Nephrol 25 (2010), 1299–1304.
22. Constantinescu, A.R., Shah, H.B., Foote, E.F., et al. Predicting first-year relapses in children with nephrotic syndrome. Pediatrics 105 (2000), 492–495.
23. Abeyagunawardena, A.S., Trompeter, R.S., Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch Dis Child 93 (2008), 226–228.
24. Gulati, A., Sinha, A., Sreenivas, V., et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6 (2011), 63–69.
25. Elzouki, A.Y., Jaiswal, O.P., Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr (Phila) 27 (1988), 387–392.
26. Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. Arch Dis Child 70 (1994), 151–157.
27. Bagga, A., Ali, U., Banerjee, S., et al. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 45 (2008), 203–214.
28. Srivastava, R.N., Vasudev, A.S., Bagga, A., et al. Long-term, low-dose prednisolone therapy in frequently relapsing nephrotic syndrome. Pediatr Nephrol 6 (1992), 247–250.
29. Kyrieleis, H.A., Lowik, M.M., Pronk, I., et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 4 (2009), 1593–1600.
30. Latta, K., von Schnakenburg, C., Ehrich, J.H., A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 16 (2001), 271–282.
31. Niaudet, P., Habib, R., Tete, M.J., et al. Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. Pediatr Nephrol 1 (1987), 566–573.
32. Boyer, O., Moulder, J.K., Grandin, L., et al. Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr Nephrol 23 (2008), 575–580.
33. Hino, S., Takemura, T., Okada, M., et al. Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis 31 (1998), 932–939.
34. Leroy, V., Baudouin, V., Alberti, C., et al. Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment. Pediatr Nephrol 24 (2009), 2393–2400.
35. Mowry, J.A., McCarthy, E.T., Cyclosporine in glomerular disease. Semin Nephrol 16 (1996), 548–554.
36. Hodson, E.M., Willis, N.S., Craig, J.C., Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev, CD002290, 2008.
37. Kyrieleis, H.A., Levtchenko, E.N., Wetzels, J.F., Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis 49 (2007), 592–597.
38. Azib, S., Macher, M.A., Kwon, T., et al. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 26 (2011), 927–932.
39. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft fur Padiatrische Nephrologie. Arch Dis Child 62 (1987), 1102–1106.
40. Williams, S.A., Makker, S.P., Ingelfinger, J.R., et al. Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. N Engl J Med 302 (1980), 929–933.
41. Wetzels, J.F., Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis?. Neth J Med 62 (2004), 347–352.
42. Miller, D.G., Alkylating agents and human spermatogenesis. JAMA 217 (1971), 1662–1665.
43. Weiss, R., Randomized double-blind placebo controlled, multi-center trial of levamisole for children with frequently relapsing/steroid dependent nephrotic syndrome (abstract). J Am Soc Nephrol, 4, 1993, 289.
44. Fu, L.S., Shien, C.Y., Chi, C.S., Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage. Nephron Clin Pract 97 (2004), c137–c141.
45. Hafeez, F., Ahmed, T.M., Samina, U., Levamisole in steroid dependent and frequently relapsing nephrotic syndrome. J Coll Physicians Surg Pak 16 (2006), 35–37.
46. Kemper, M.J., Amon, O., Timmermann, K., et al. [The treatment with levamisole of frequently recurring steroid-sensitive idiopathic nephrotic syndrome in children]. Dtsch Med Wochenschr 123 (1998), 239–243.
47. Palcoux, J.B., Niaudet, P., Goumy, P., Side effects of levamisole in children with nephrosis. Pediatr Nephrol 8 (1994), 263–264.
48. Niaudet, P., Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 6 (1992), 1–3.
49. Ponticelli, C., Edefonti, A., Ghio, L., et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 8 (1993), 1326–1332.
50. Yoshioka, K., Ohashi, Y., Sakai, T., et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 58 (2000), 317–324.
51. El-Husseini, A., El-Basuony, F., Mahmoud, I., et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant 20 (2005), 2433–2438.
52. Hulton, S.A., Neuhaus, T.J., Dillon, M.J., et al. Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood. Pediatr Nephrol 8 (1994), 401–403.
53. Niaudet, P., Broyer, M., Habib, R., Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol 35:Suppl 1 (1991), S31–S36.
54. Ishikura, K., Ikeda, M., Hattori, S., et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int 73 (2008), 1167–1173.
55. Filler, G., How should microemulsified Cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored?. Nephrol Dial Transplant 20 (2005), 1032–1034.
56. Sinha, M.D., MacLeod, R., Rigby, E., et al. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 21 (2006), 1848–1854.
57. Dotsch, J., Dittrich, K., Plank, C., et al. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A?. Nephrol Dial Transplant 21 (2006), 1761–1763.
58. Iijima, K., Hamahira, K., Tanaka, R., et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61 (2002), 1801–1805.
59. Kranz, B., Vester, U., Buscher, R., et al. Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol 23 (2008), 581–586.
60. El-Husseini, A., El-Basuony, F., Mahmoud, I., et al. Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome. Eur J Clin Pharmacol 62 (2006), 3–8.
61. Dorresteijn, E.M., Kist-van Holthe, J.E., Levtchenko, E.N., et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23 (2008), 2013–2020.
62. Hogg, R.J., Fitzgibbons, L., Bruick, J., et al. Clinical trial of mycophenolate mofetil (MMF) for frequent relapsing nephrotic syndrome in children (abstract). Pediatr Nephrol, 19, 2004, C66.
63. Afzal, K., Bagga, A., Menon, S., et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 22 (2007), 2059–2065.
64. Barletta, G.M., Smoyer, W.E., Bunchman, T.E., et al. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 18 (2003), 833–837.
65. Ettenger, R., Bartosh, S., Choi, L., et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 9 (2005), 780–787.
66. Ravani, P., Magnasco, A., Edefonti, A., et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6 (2011), 1308–1315.
67. Guigonis, V., Dallocchio, A., Baudouin, V., et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23 (2008), 1269–1279.
68. Prytula, A., Iijima, K., Kamei, K., et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25 (2010), 461–468.
69. Chaumais, M.C., Garnier, A., Chalard, F., et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24 (2009), 1753–1755.
70. Gulati, S., Sharma, A.P., Sharma, R.K., et al. Do current recommendations for kidney biopsy in nephrotic syndrome need modifications?. Pediatr Nephrol 17 (2002), 404–408.
71. Gulati, S., Sural, S., Sharma, R.K., et al. Spectrum of adolescent-onset nephrotic syndrome in Indian children. Pediatr Nephrol 16 (2001), 1045–1048.
72. Baqi, N., Singh, A., Balachandra, S., et al. The paucity of minimal change disease in adolescents with primary nephrotic syndrome. Pediatr Nephrol 12 (1998), 105–107.
73. Gipson, D.S., Chin, H., Presler, T.P., et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 21 (2006), 344–349.
74. Gorensek, M.J., Lebel, M.H., Nelson, J.D., Peritonitis in children with nephrotic syndrome. Pediatrics 81 (1988), 849–856.
75. Ulinski, T., Leroy, S., Dubrel, M., et al. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol 23 (2008), 1107–1113.
76. Aoun, B., Wannous, H., Azema, C., et al. Polysaccharide pneumococcal vaccination of nephrotic children at disease onset-long-term data. Pediatr Nephrol 25 (2010), 1773–1774.
77. The Australian immunisation handbook, Australian Government Department of Health and Ageing. 2008 Office of Health Protection: Woden, ACT,.
78. American Academy of Pediatrics, Section1: Active and passive immunization. Pickering, L.K., Baker, C.J., Long, S.S., McMillan, J.A., (eds.) Red Book: 2006 Report of the Committee on Infectious Diseases, 27th edn., 2006, 1–103 Elk Grove Village, IL.